ערך בספרים למניה: Tiziana Life Sciences (TLSA)

Tiziana Life Sciences (TLSA) relies on rigorous planning and external GMP contractors for the production of monoclonal antibodies for inhalation to eliminate deadline failures, with the current metric standing at -0.02. This price action chart helps track this sector. The business is based on developing nasal agents to combat neuroinflammation in Alzheimer's and sclerosis, integrating comfortable immunotherapy methods into the overall therapeutic environment.

For Tiziana Life Sciences (TLSA), which is developing innovative nasal immunotherapy for multiple sclerosis, this indicator reflects the actual net asset value per share. By analyzing the history of book value per share, an investor assesses the company's residual equity minus liabilities, allowing for a comparison of the company's fundamental base against the clinical trial costs of foralumab.